Acute coronary syndromes refer to any constellation of clinical symptoms compatible with acute myocardial ischemia which may be life-threatening.
It encompasses unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).
Unstable angina is the ischemic discomfort that presents without persistent ST-segment elevation on ECG and without the presence of cardiac markers in the blood.
Non-ST-segment elevation myocardial infarction is diagnosed if cardiac markers are positive with ST-segment depression or with nonspecific or normal ECGs.
The patient typically presents with ischemic-type chest pain that is severe and prolonged and may occur at rest or may be caused by less exertion than previous episodes.
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Taking marine-derived omega-3 fatty acid (FA) supplements does not appear to protect participants from coronary heart disease (CHD) and major vascular events, regardless of history of vascular disease, lipid levels, statin use, or diabetes, suggests a recent meta-analysis.
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.
Adding coronary artery calcium (CAC) scores to the traditional Framingham risk score may improve cardiovascular disease (CVD) risk classification in patients with metabolic syndrome or type 2 diabetes (T2D) than using traditional score alone, even in those with diabetes for over 10 years, according to the MESA* study.
A 6-month dual antiplatelet therapy (DAPT) was noninferior to the recommended 12-month regimen in STEMI* patients undergoing primary percutaneous intervention (PCI) with a second-generation drug-eluting stent (DES), according to the DAPT-STEMI study presented at the TCT 2017 Congress.
A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.
Using bioabsorbable polymer drug-eluting stents (DES) with a shorter duration of double antiplatelet therapy (DAPT) in elderly patients undergoing percutaneous coronary intervention (PCI) leads to fewer adverse events than bare-metal stents (BMS) without increasing bleeding risk, according to the SENIOR* trial presented at TCT 2017 Congress.
Performing percutaneous coronary intervention (PCI) on culprit lesion only, rather than a multivessel PCI, reduces the 30-day composite risk of death or severe renal failure in patients with acute myocardial infarction (MI) complicated by cardiogenic shock and multivessel disease, according to the CULPRIT-SHOCK* study presented at the TCT 2017 Congress held in Denver, Colorado, US.
Tai Chi may be a promising exercise alternative to improve physical activity in patients with coronary heart disease (CHD) who are unable or unwilling to participate in conventional cardiac rehabilitation (CR), a new study suggests.
Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.